<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076514</url>
  </required_header>
  <id_info>
    <org_study_id>Ahmed1712</org_study_id>
    <nct_id>NCT04076514</nct_id>
  </id_info>
  <brief_title>The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma</brief_title>
  <acronym>pCND</acronym>
  <official_title>The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The benefits of prophylactic central neck dissection (pCND) remain controversial in
      clinically node-negative (cN0) papillary thyroid carcinoma (PTC). This study main goal is to
      investigate benefits of prophylactic central neck dissection in clinically node-negative
      papillary thyroid carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid
      carcinoma. Recurrence rate is still high. The standard management is total thyroidectomy.
      regional lymph node metastasis is noted in recurrent cases. Some studies stated benefits of
      central neck dissection in orevention of recurrence and others said there is no benefits. so
      prophylactic central neck dissection (pCND) remain controversial in clinically node-negative
      (cN0) papillary thyroid carcinoma (PTC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence metastatic lymph node in patients with clinically node-negative thyroid carcinoma who underwent total thyroidectomy with central neck dissection</measure>
    <time_frame>12 months</time_frame>
    <description>numbers of positive histopathological lymph node biopsies postoperative</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Papillary Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>patients with node negative papillary thyroid carcinoma</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>central neck dissection</intervention_name>
    <description>dissection of central cervical lymph node grope in low grade papillary thyroid cancer</description>
    <arm_group_label>patients with node negative papillary thyroid carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with papillary thyroid carcinoma with clinically negative lymph node who undergo
        total thyroidectomy and central neck dissetion in assiut university hospital, department of
        general surgery.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with papillary thyroid cancer with clinically node negative.

        Exclusion Criteria:

          -  patients with clinical evidence of nodal metastases.

          -  patients with a previous history of thyroidectomy.

          -  patients with mixed-type papillary thyroid cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ahmed kamel ali</last_name>
    <phone>00201021259455</phone>
    <email>ahmed01155@med.aun.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ahmed Kamel</name>
      <address>
        <city>Asyūţ</city>
        <state>Asyut</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ahmed kamel ali</last_name>
      <phone>00201021259455</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed Kamel Ali</investigator_full_name>
    <investigator_title>resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

